Abstract:
The present invention relates to a mobile protection system for moored or anchored ships. The system has a reinforced foldable surface unit and a foldable net unit connected to the surface unit to provide a restricted area. The surface unit prevents small boats from entering the area and the net unit prevents divers from entering the area. The net unit is provided with an alarm to indicate if a diver tries to penetrate the net.
Abstract:
The invention relates to an equipment for removing deposits accumulated in electrolytic refining on the surface of an electrode, such as a cathode, said equipment including at least one element for stripping the deposits and at least one element for controlling the stripping element; said equipment includes at least one stripping element that is turnably movable in the vertical direction of the cathode, and the cathode can be bent owing to the contact with said stripping element. The invention also relates to a method realized by said equipment.
Abstract:
A novel strain of Lactobacillus plantarum, referred to as LB931, has now been isolated. The strain has been deposited at Deutsche Sammlung von Mikroorganismen, Braunschweig, DE. It has been assigned accession number DSM11918. Accordingly LB931 can be used for treating and/or preventing urogenital infections. LB931 can advantageously be included in pharmaceutical compositions and in products for personal care, such as feminine hygiene products, diapers and sanitary napkins.
Abstract translation:一种新型的植物乳杆菌菌株(简称LB931)现已被分离出来。 菌株已经存放在德国不伦瑞克的德意志山姆·米克罗维尼森(Deutsche Sammlung von Mikroorganismen)。 已分配保藏号DSM11918。 因此,LB931可用于治疗和/或预防泌尿生殖器感染。 LB931可有利地包括在药物组合物和用于个人护理的产品中,例如女性卫生产品,尿布和卫生巾。
Abstract:
The invention relates to a packing trough adapted to be provided with a lid, consisting of a bottom and walls formed of a coherent blank and a lid preferably also coherent therewith and formed of the same blank.The trough consists of a flat bottom section, lower wall sections sloping upwards and outwards therefrom and upper wall sections being generally perpendicular to the bottom, and there is at each of the corners between the lower wall sections a doubled portion which is folded so as to be coplanar with one of the lower wall sections adjoining such a corner and which is attached to said corner, said portion having a projection which also is doubled but folded so as to be coplanar with one of the upper wall sections, and attached thereto, said doubled portions and said equally doubled projections being adapted to seal the corners of the trough.
Abstract:
A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipients, wherein X, R, R, R, and R are as defined herein. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering to said patient the first component and the second component.
Abstract:
Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y represents a bond, an oxygen atom or NR6; R6 is a hydrogen atom, COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more selected from COOR8, CONR82, NR82, OR8, ═NR8, ═O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents C1-8 alkylene, 1,2-cykloalkylene, or 1,2-arylene, optionally substituted with R7; and R4 represents hydrogen or C1-3 alkyl.
Abstract:
Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y represents a bond, an oxygen atom or NR6; R6 is a hydrogen atom, COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more selected from COOR8, CONR82, NR82, OR8, ═NR8, ═O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents C1-8 alkylene, 1,2-cykloalkylene, or 1,2-arylene, optionally substituted with R7; and R4 represents hydrogen or C1-3 alkyl.
Abstract:
The disclosure relates to a method for supplying, with a lance (11), a liquid to a heat treatment oven, the liquid being vaporized by the oven heat and being introduced into the oven with the aid of a carrier gas, and a lance (11) for carrying the method into effect.According to the method, the liquid is, with a carrier gas, atomized in an end of the lance (11) facing away from the interior of the oven, the atomized liquid and the carrier gas being supplied to a vaporization chamber (12) with an outlet aperture (14) directed towards the interior of the oven, in which chamber (12) the atomized liquid is vaporized by the oven heat during simultaneous cooling of the chamber (12), and the thus formed vapor and carrier gas are caused to depart from the vaporization chamber (12) of the lance (11) through the aperture designed as a nozzle (22).The lance (11) includes a vaporization chamber (12) with an inlet (13) for the liquid and the carrier gas in one end of the lance (12), and an outlet (14) in the other end of the chamber (12), and a liquid atomizing nozzle (15) in the inlet (13) of the chamber (12).
Abstract:
A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipients, wherein X, R, R, R, and R are as defined herein. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering to said patient the first component and the second component.
Abstract:
A conveyor comprises perforation bands arranged in the floor of a storage space. Some of the bands emit an air stream that in quantity or pressure differs from the air stream in the remaining bands and have apertures with a larger flow area than the apertures in the remaining bands. The larger apertures are provided: along with a first perforation band placed in the middle of a sector of the floor and extending across the entire sector; along one further band arranged on one side of the first band with a shorter extension than in the first band; and in portions of bands which portions are closest to the walls of the storage space.